Initial digest — SIRT3 receipt

what this node claims

Initial digest — SIRT3

AlphaFold v6 prediction landed for **SIRT3** (NAD-dependent deacetylase sirtuin-3 (mitochondrial)). UniProt accession: `Q9NTG7`. Lane: `longevity`. Mean per-residue pLDDT: **75.35**. Mitochondrial-localized; cell-pene...

Open source surface

vertical proof spine

evidence / risk instrument

39%

thin proof

low debt pressure 29%

28%structuredebt

pLDDT pending

55%evidencethin

grade C

0%gatesdebt

0/5 gates

100%riskstrong

0 hard flags

22%exportdebt

no export

33%lineagedebt

incomplete spine

proof completeness

33% missing target, alphafold_metric, candidate, export

01 target
02 fold
03 alphafold metric
04 candidate
05 finding
06 export

Metrics and receipt inputs

confidence: 0.6
evidence refs: 1

AlphaFold metrics visual

Confident backbone model

75.3

399 residues / min 22.61 / max 98.94 / source alphafold db

Very high 58.9% 235 residues / >=90

Confident 7.0% 28 residues / 70-89

Low 5.0% 20 residues / 50-69

Very low 29.1% 116 residues / <50

usable fold context with explicit model-confidence limits

Near-complete coverage / observed 399 of 399 residues.

residues 1-121 / mean 34.62
residues 157-167 / mean 66.2
residues 396-399 / mean 47.16

proof debt register

Visible limits, not hidden cleanup.

29%

Peptide RX keeps unresolved proof debt attached to the public receipt. Some debts should be resolved; redaction and research-use boundaries should stay visible.

high low evidence grade attach graded finding with source-linked evidence

low computational-only status add independent evidence, challenge result, or witness review before strengthening

medium no candidate yet leave visible until a stronger public receipt resolves it

Initial digest — SIRT3